Fresenius Biotech develops its approved antibodies in international clincial studies for further indications and various development phases.

Approved antibodies in clinical studies

• Catumaxomab (Removab®)
• Anti T-lymphocyte globulin (ATG-Fresenius® S)

All studies that Fresenius Biotech funds or co-funds as a sponsor are listed in a public clinical trials registry.

All relevant information on our clinical studies can be found at www.clinicaltrials.gov.

Note on study information
The information provided in the registry is not a replacement for medical advice from a physician or pharmacist. Before deciding on a particular treatment or participation in a study, be sure to seek the medical advice of the doctor treating the illness or disease.